226 related articles for article (PubMed ID: 20460522)
1. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
Nimmagadda S; Pullambhatla M; Stone K; Green G; Bhujwalla ZM; Pomper MG
Cancer Res; 2010 May; 70(10):3935-44. PubMed ID: 20460522
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
3. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
4. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.
De Silva RA; Peyre K; Pullambhatla M; Fox JJ; Pomper MG; Nimmagadda S
J Nucl Med; 2011 Jun; 52(6):986-93. PubMed ID: 21622896
[TBL] [Abstract][Full Text] [Related]
5.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
Hartimath SV; van Waarde A; Dierckx RA; de Vries EF
Mol Pharm; 2014 Nov; 11(11):3810-7. PubMed ID: 25094028
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 regulates growth of both primary and metastatic breast cancer.
Smith MC; Luker KE; Garbow JR; Prior JL; Jackson E; Piwnica-Worms D; Luker GD
Cancer Res; 2004 Dec; 64(23):8604-12. PubMed ID: 15574767
[TBL] [Abstract][Full Text] [Related]
8. Development and Evaluation of an
Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
10. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
11. CXCR4-targeted PET imaging using
Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
[No Abstract] [Full Text] [Related]
12. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
Nimmagadda S; Pullambhatla M; Pomper MG
J Nucl Med; 2009 Jul; 50(7):1124-30. PubMed ID: 19525448
[TBL] [Abstract][Full Text] [Related]
13. Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis.
Zhao Y; Detering L; Sultan D; Cooper ML; You M; Cho S; Meier SL; Luehmann H; Sun G; Rettig M; Dehdashti F; Wooley KL; DiPersio JF; Liu Y
ACS Nano; 2016 Jun; 10(6):5959-70. PubMed ID: 27159079
[TBL] [Abstract][Full Text] [Related]
14.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
15. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
16. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4.
Cronin PA; Wang JH; Redmond HP
BMC Cancer; 2010 May; 10():225. PubMed ID: 20492653
[TBL] [Abstract][Full Text] [Related]
19. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
[TBL] [Abstract][Full Text] [Related]
20. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
Poty S; Désogère P; Goze C; Boschetti F; D'huys T; Schols D; Cawthorne C; Archibald SJ; Maëcke HR; Denat F
Dalton Trans; 2015 Mar; 44(11):5004-16. PubMed ID: 25640878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
